L.M. Rapoport, E.A. Bezrukov, Ju.L. Demidko, A.V. Kondrashina Application of diferelin and its perspectives


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents a brief overview of luteinizing hormone-releasing hormone analogs in the treatment of prostate cancer. The authors report their experience with this drug class by an example of Diferelin. The experience with abiraterone in treatment of patients with hormonal resistance is described.

Full Text

Restricted Access

About the authors

L. M Rapoport

Research Institute of Uronephrology and Human Reproductive Health

E. A Bezrukov

Research Institute of Uronephrology and Human Reproductive Health

Ju. L Demidko

Research Institute of Uronephrology and Human Reproductive Health

Email: demidko1@maiI.ru
Ph.D., Head of Department of Functional Diagnostics And Treatment Methods of Research Institute of Uronephrology and Human Reproductive Health

A. V Kondrashina

Research Institute of Uronephrology and Human Reproductive Health

References

  1. Оха У.К., Логью Дж. Рак простаты. М.: Рид Элсивер, 2009.
  2. Матвеев Б.П. Эпидемиология рака предстательной железы. Под ред. Б.П.Матвеева. Клиническая онкоурология. М.:Вердана, 2003.
  3. Shally A. V., Arimura A., Baba Y., Nair R.M., Matsuo H., Redding T. W., Debeljuk L. Isolation and properties of the FSH and LH-releasing hormone. Biohem. Biophys. Res. Commun. 1971;43(2):393-399.
  4. Портной А.С. Новые аспекты антиандрогенной терапии рака предстательной железы. Урол. и нефрол. 1985;3:69-73.
  5. Schally A.V. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumourigenesis. Peptides. 1999;20(10): 1247-62.
  6. Limonta P., Montagnani M.M., Moretti R.M. LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin Investig Drugs. 2001;10(4):709-720.
  7. Akaza H., Homma Y., Okada K., Yokoyama M., Moriyama N., Usami M., Hirao Y., Tsushima T., Ohashi Y., Aso Y. Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate c: a prospective and randomized study. The Prostate Cancer Study Group. Jpn. J. Clin. Oncol. 2000; 30(3) :131-136.
  8. Schmid H.P., Bitton A. Therapeutic options in advanced cancer of the prostate. Schweiz Rundsch Med. Prax. 1997; 86(44): 1734- 17 39.
  9. Seidenfeld J., Samson D.J., Hasselblad V., Aronson N., Albertsen P.C., Bennett C. L., Wilt T.J. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann. Intern. Med. 2000;132(7):566-577.
  10. Tyrrell C.J., Altwein J.E., Klippel F., Jurincic-Winkler C., Varen-horst E., Lunglmayr G., Boccardo F., Holdaway I.M., Haefliger J.M., Jordaan J.P. Comparison of an LH-RH analogue (Goeserelin acetate, 'Zoladex') with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group. Eur. Urol. 200;37(2):205-211.
  11. Tyrrell C.J. Adjuvant and neoadjuvant hormonal therapy for pros-tate cancer. Eur. Urol. 1999;36(6):549-558.
  12. Sundkvist G.M., Bjork T., Kjellstrom H., Lilja B. Quantitative bone scintigraphy in patients with prostatic carcinoma treated with LH-RH analogues. Scand. J. Urol. Nephrol. 1996; 30 (1):29-32.
  13. Yamamoto A., Sumiyoshi Y., Miyake N., Yokozeki H., Kanayama H., Kagawa S. Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue. Hinyokika Kiyo. 1998;44(8):557-563.
  14. Ueda S., Nishi K., Yoshida M. Assessment of the quality of life (QOL) of prostatic cancer patients under LH-RH analogue treatment. Nippon Rinsho. 1998;56(8):2119-2123.
  15. Kameyama S., Yamazaki S., Kitamura. Surgical or medical castration with LH-RH analogue for prostatic cancer. Nippon Rinsho. 1998;56(8): 2114-2118.
  16. Mizusawa H., Kontani K., Okaneya T., Yoneyama T. Luteinizing hormonereleasing hormone for prostate cancer in a hemodialysis patient: a case report. Hinyokika Kiyo. 1997;43(6):421-423.
  17. Tunn U.W., Bargelloni U., Cosciani S., Fiaccavento G., Guazzieri S., Pagano F. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer. Urol. Int. 1998;60(1):9-16.
  18. Labarthe M.P., Bayle-Lebey P., Bazex J. Cutaneous manifestations of relapsing polychondritis in a patient receiving goserelin for carcinoma of the prostate. Dermatology. 1997;195(4):391-394.
  19. Матвеев Б.П., Бухаркин Б.В. Лечение диссеминированного рака предстательной железы Золадексом. Матер. конф. «Применение Золадекса при раке предстательной железы». М., 1995.
  20. Oefelein M.G., Cornum R. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm. J. Urol. 2000;164(3, Pt 1):726-729.
  21. Heidenreich A., Bolla M., Joniau S., Mason M.D., Matveev V., Mottet N., Schmid H-P., van der Kwast T.H., Wiege T., Zattoni F. Guidelines on Prostate Cancer. s.l. European Association of Urology, 2010.
  22. Heidenreich A., Bolla M., Joniau S., Mason M. D., Matveev V., Mottet N., Schmid H-P., van der Kwast T. H., Wiegel T., Zattoni F. EAU guideline. 2011.
  23. Матвеев В.Б., Волкова М.И. Роль дегареликса (Фирмагон) в лечении распространенного рака предстательной железы: можно ли улучшить качество кастрационной терапии? Онкоурология. 2011;1:66-71.
  24. Geller J., Albert J., Vik A. Advantages of total androgen blockade in the treatment of advanced prostate cancer. Semin. Oncol. 1988;15 (2 Suppl. 1):53-61.
  25. Labrie F., Dupont A., Belanger A., Lacoursiere Y., Raynaud J.P., Husson J.M., Gareau J., Fazekas A.T., Sandow J., Monfette G., et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate. 1983;4(6):579-594.
  26. Heidenreich A., Porres D., Epplen R., van Erps T., Pfister D. Change of the LHRH analogue in progressive castration-refractory prostate cancer. Urologe. 2012;51(9):1282-1287.
  27. Heyns C.F., Simonin M.-P., Grosgurin P., Schall R., Porchet H.C. Comparative efficacy of triptorelin pamoat and leuprolide acetate in men with advanced prostate cancer. BJU Int. 2003;92:226-231.
  28. Gravanis I., Lopez A.S., Hemmings R.J., Jimenez J.C., Garcia-Carbonero R., Gallego I.G., Gimenez E.V., O'Connor D., Giuliani R., Salmonson T., Pignatti F. The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naive disease: summary of the scientific assessment of the committee for. Oncologist. 2013;18(9):1032-1042.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies